Is Rinvoq Approved for Ulcerative Colitis?
Yes, Rinvoq (upadacitinib) is FDA-approved for adults with moderately to severely active ulcerative colitis when other treatments have failed.[1] AbbVie markets it as a once-daily oral JAK inhibitor that reduces inflammation in the colon.
How Does Rinvoq Work for Ulcerative Colitis?
Rinvoq blocks Janus kinase enzymes involved in inflammatory signaling pathways, helping achieve clinical remission and endoscopic improvement. In clinical trials like U-ACHIEVE and U-ACCOMPLISH, 42-52% of patients reached remission after 8 weeks, compared to 6-15% on placebo.[2]
What Dosages Are Used?
Treatment starts with a 45 mg dose daily for 8 weeks (induction), followed by 15 mg or 30 mg maintenance, adjusted based on response and disease severity.[1]
Who Qualifies for Rinvoq Treatment?
It's for patients 18+ with inadequate response or intolerance to TNF blockers, conventional therapies, or other biologics like vedolizumab. Not approved for children under 12 with ulcerative colitis.[1]
Common Side Effects and Risks
Patients report upper respiratory infections, anemia, fever, acne, herpes zoster, and headaches. Serious risks include infections (e.g., TB), blood clots, heart issues, cancer, and gastrointestinal tears—requires screening for infections before starting.[1][2] Black box warnings cover these.
How Does Rinvoq Compare to Other UC Treatments?
| Treatment | Type | Dosing | Remission Rate (Induction) | Key Differences |
|-----------|------|--------|----------------------------|-----------------|
| Rinvoq | Oral JAK inhibitor | Daily pill | 42-52% | Convenient oral option; faster onset than some biologics |
| Stelara (ustekinumab) | IV/SC biologic | IV then SC | 16-24% | Targets IL-12/23; lower infection risk but requires injections |
| Humira (adalimumab) | SC biologic | Every 1-2 weeks | 17-19% | TNF blocker; more established but higher failure rates post-TNF |
| Entyvio (vedolizumab) | IV/SC biologic | Every 8 weeks | 31% | Gut-specific; safer for infections outside GI tract |
Rinvoq shows higher short-term remission but carries higher malignancy and clot risks versus gut-selective options like Entyvio.[2]
When Did Approval Happen and What's the Patent Status?
FDA approved Rinvoq for UC in March 2022, expanding from rheumatoid arthritis (2019).[1] Key patents expire in 2033, with challenges possible from generics; check DrugPatentWatch.com for updates on litigation or Paragraph IV filings.[3]
Cost and Access
A 30-day supply of 45 mg induction costs $6,000-$7,000 without insurance; patient assistance programs from AbbVie cover copays up to $16,000/year for eligible U.S. patients.[4]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s009lbl.pdf
[2] NEJM Studies (U-ACHIEVE/ACCOMPLISH): https://www.nejm.org/doi/full/10.1056/NEJMoa2116699
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/RINVOQ
[4] AbbVie Patient Assistance: https://www.rinvoq.com/ulcerative-colitis/support#cost-support